Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders

A Antonelli; A D'Andrea; A Monaco; AL Zignego; AL Zignego; Amalia De Renzo; Annacarmen Petrizzo; B Abayli; C Chougnet; C Ferri; C Ferri; C Ferri; D Gaucher; D Moradpour; D Piccioli; D Sansonno; Debora Martorelli; E Aricò; E Zuckerman; ED Charles; EE Murphy; F Dammacco; F Sallusto; Franco M Buonaguro; Gerardo Beneduce; Giuseppe Castello; J Stebbing; K Machida; L Buonaguro; L Buonaguro; L Buonaguro; L Buonaguro; LA Martyak; Luca Romagnoli; Luigi Buonaguro; M Bendandi; M Kobayashi; M Kubin; M Perotti; M Reiser; Maria Napolitano; Marialina Tornesello; NE Spanakis; Oreste Perrella; P Pileri; R Misiani; Riccardo Dolcetti; RS Longman; TD Querec; V De Re; V De Re; V De Re; V De Re; Valli De Re; Vitor Sousa; XG Fan; XL Huang; Z Fan

Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders

Abstract

Hepatitis C virus (HCV) is one of the major risk factors for chronic hepatitis, which may progress to cirrhosis and hepatocellular carcinoma, as well as for type II mixed cryoglobulinemia (MC), which may further evolve into an overt B-cell non-Hodgkin's lymphoma (NHL)